These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 29445178

  • 41. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
    Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, Sokol H, Coffin B, Sabaté JM.
    Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
    [Abstract] [Full Text] [Related]

  • 42. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Andresen V, Gschossmann J, Layer P.
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):658-666. PubMed ID: 32277872
    [Abstract] [Full Text] [Related]

  • 43. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome.
    Dolin BJ.
    Methods Find Exp Clin Pharmacol; 2009 Dec; 31(10):655-9. PubMed ID: 20140275
    [Abstract] [Full Text] [Related]

  • 44. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota.
    Huang HL, Chen HT, Luo QL, Xu HM, He J, Li YQ, Zhou YL, Yao F, Nie YQ, Zhou YJ.
    J Dig Dis; 2019 Aug; 20(8):401-408. PubMed ID: 31070838
    [Abstract] [Full Text] [Related]

  • 45. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation.
    Mazzawi T, Lied GA, Sangnes DA, El-Salhy M, Hov JR, Gilja OH, Hatlebakk JG, Hausken T.
    PLoS One; 2018 Aug; 13(11):e0194904. PubMed ID: 30427836
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Therapeutic Effect of Chang'an I Recipe ( I ) on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Tang XD, Lu B, Li ZH, Wei W, Meng LN, Li BS, Tang ZP, Gao R, Wang FY, Lu F, Bian LQ, Zhao YP, Wang P, Zhang YQ.
    Chin J Integr Med; 2018 Sep; 24(9):645-652. PubMed ID: 27487786
    [Abstract] [Full Text] [Related]

  • 48. Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome.
    Mizuno S, Masaoka T, Naganuma M, Kishimoto T, Kitazawa M, Kurokawa S, Nakashima M, Takeshita K, Suda W, Mimura M, Hattori M, Kanai T.
    Digestion; 2017 Sep; 96(1):29-38. PubMed ID: 28628918
    [Abstract] [Full Text] [Related]

  • 49. Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized, multiple-blind, placebo-controlled trial.
    Liang SB, Han M, Cheng HJ, Zhang QY, Zhang NW, Jia BY, Robinson N, Liu JP.
    Trials; 2022 Mar 21; 23(1):226. PubMed ID: 35313933
    [Abstract] [Full Text] [Related]

  • 50. A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, Miele E, Staiano A.
    J Clin Gastroenterol; 2017 Jan 21; 51(1):e5-e10. PubMed ID: 27306945
    [Abstract] [Full Text] [Related]

  • 51. Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial.
    Bao C, Zhang J, Liu J, Liu H, Wu L, Shi Y, Li J, Hu Z, Dong Y, Wang S, Zeng X, Wu H.
    BMC Complement Altern Med; 2016 Oct 24; 16(1):408. PubMed ID: 27776494
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
    Didari T, Mozaffari S, Nikfar S, Abdollahi M.
    World J Gastroenterol; 2015 Mar 14; 21(10):3072-84. PubMed ID: 25780308
    [Abstract] [Full Text] [Related]

  • 54. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R.
    Lancet Gastroenterol Hepatol; 2018 Jan 14; 3(1):17-24. PubMed ID: 29100842
    [Abstract] [Full Text] [Related]

  • 55. Fecal microbiota transplantation in patients with irritable bowel syndrome: an overview of current studies.
    Körner E, Lorentz A.
    J Appl Microbiol; 2023 Mar 01; 134(3):. PubMed ID: 36882216
    [Abstract] [Full Text] [Related]

  • 56. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study.
    Azpiroz F, Dubray C, Bernalier-Donadille A, Cardot JM, Accarino A, Serra J, Wagner A, Respondek F, Dapoigny M.
    Neurogastroenterol Motil; 2017 Feb 01; 29(2):. PubMed ID: 27477485
    [Abstract] [Full Text] [Related]

  • 57. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.
    Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C.
    Aliment Pharmacol Ther; 2007 Aug 01; 26(3):475-86. PubMed ID: 17635382
    [Abstract] [Full Text] [Related]

  • 58. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
    Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC.
    Aliment Pharmacol Ther; 2019 Aug 01; 50(3):240-248. PubMed ID: 31136009
    [Abstract] [Full Text] [Related]

  • 59. Efficacy of Probiotic Escherichia coli Nissle 1917 in Patients with Irritable Bowel Syndrome: a Double Blind Placebo-controlled Randomized Trial.
    Faghihi AH, Agah S, Masoudi M, Ghafoori SM, Eshraghi A.
    Acta Med Indones; 2015 Jul 01; 47(3):201-8. PubMed ID: 26586385
    [Abstract] [Full Text] [Related]

  • 60. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y, Hong G, Yang M, Li G, Jin Y, Xiong H, Qian W, Hou X.
    Pharmacol Res; 2020 Sep 01; 159():104936. PubMed ID: 32470562
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.